
ATLANTA-A prospective study, presented at the 35th Annual Meeting of the American Society of Clinical Oncology, has found the utility of routine endometrial biopsy among women with breast cancer treated with tamoxifen (Nolvadex) to be “limited at best.” Another study presented at the meeting finds sonography to be inadequate as a substitute for endometrial biopsy in healthy women receiving tamoxifen prophylaxis.
